Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study

被引:56
|
作者
Walker, Venexia M. [1 ,2 ]
Kehoe, Patrick G. [3 ,4 ]
Martin, Richard M. [1 ,2 ]
Davies, Neil M. [1 ,2 ]
机构
[1] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol, Avon, England
[2] Univ Bristol, Bristol Med Sch Populat Hlth Sci, Bristol, Avon, England
[3] Univ Bristol, Dementia Res Grp, Bristol, Avon, England
[4] Univ Bristol, Bristol Med Sch Translat Hlth Sci, Bristol, Avon, England
基金
英国医学研究理事会;
关键词
Mendelian randomization; drug repurposing; Alzheimer's disease; hypertension; antihypertensive drugs; BLOOD-PRESSURE; INSTRUMENTS; RISK;
D O I
10.1093/ije/dyz155
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Evidence concerning the potential repurposing of antihypertensives for Alzheimer's disease prevention is inconclusive. We used Mendelian randomization, which can be more robust to confounding by indication and patient characteristics, to investigate the effects of lowering systolic blood pressure, via the protein targets of different antihypertensive drug classes, on Alzheimer's disease. Methods: We used summary statistics from genome-wide association studies of systolic blood pressure and Alzheimer's disease in a two-sample Mendelian randomization analysis. We identified single-nucleotide polymorphisms (SNPs) that mimic the action of antihypertensive protein targets and estimated the effect of lowering systolic blood pressure on Alzheimer's disease in three ways: (i) combining the protein targets of antihypertensive drug classes, (ii) combining all protein targets and (iii) without consideration of the protein targets. Results: There was limited evidence that lowering systolic blood pressure, via the protein targets of antihypertensive drug classes, affected Alzheimer's disease risk. For example, the protein targets of calcium channel blockers had an odds ratio (OR) per 10 mmHg lower systolic blood pressure of 1.53 [95% confidence interval (CI): 0.94 to 2.49; p= 0.09; SNPs = 17]. We also found limited evidence for an effect when combining all protein targets (OR per 10 mmHg lower systolic blood pressure: 1.14; 95% CI: 0.83 to 1.56; p= 0.41; SNPs = 59) and without consideration of the protein targets (OR per 10 mmHg lower systolic blood pressure: 1.04; 95% CI: 0.95 to 1.13; p= 0.45; SNPs = 153). Conclusions: Mendelian randomization suggests that lowering systolic blood pressure via the protein targets of antihypertensive drugs is unlikely to affect the risk of developing Alzheimer's disease. Consequently, if specific antihypertensive drug classes do affect the risk of Alzheimer's disease, they may not do so via systolic blood pressure.
引用
收藏
页码:1132 / 1140
页数:9
相关论文
共 50 条
  • [21] Alzheimer Disease and Epilepsy A Mendelian Randomization Study
    Fang, Yi
    Si, Xiaoli
    Wang, Jiali
    Wang, Zhiyun
    Chen, Ying
    Liu, Yi
    Yan, Yaping
    Tian, Jun
    Zhang, Baorong
    Pu, Jiali
    NEUROLOGY, 2023, 101 (04) : E399 - E409
  • [22] Life Course Adiposity and Alzheimer's Disease: A Mendelian Randomization Study
    Li, Xian
    Tian, Yan
    Yang, Yu-Xiang
    Ma, Ya-Hui
    Shen, Xue-Ning
    Chen, Shi-Dong
    Dong, Qiang
    Tan, Lan
    Yu, Jin-Tai
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 (02) : 503 - 512
  • [23] Association of autoimmune diseases with Alzheimer?s disease: A mendelian randomization study
    Yeung, Chris Ho Ching
    Yeung, Shiu Lun Au
    Schooling, C. Mary
    JOURNAL OF PSYCHIATRIC RESEARCH, 2022, 155 : 550 - 558
  • [24] White Matter and Alzheimer’s Disease: A Bidirectional Mendelian Randomization Study
    Yaqing Li
    Jiaxin Zheng
    Tian Li
    Junjian Zhang
    Neurology and Therapy, 2022, 11 : 881 - 892
  • [25] Childhood obesity and risk of Alzheimer's disease: a Mendelian randomization study
    Qing, Wenxiang
    Qian, Yujie
    ARCHIVES OF PUBLIC HEALTH, 2024, 82 (01)
  • [26] Working status and risk of Alzheimer's disease: A Mendelian randomization study
    Zhao, Jiaxi
    Li, Kaixin
    Liao, Xiaoyang
    BRAIN AND BEHAVIOR, 2023, 13 (01):
  • [27] Amyloid, tau and risk of Alzheimer’s disease: a Mendelian randomization study
    Chris Ho Ching Yeung
    Kathleen Wen Din Lau
    Shiu Lun Au Yeung
    C. Mary Schooling
    European Journal of Epidemiology, 2021, 36 : 81 - 88
  • [28] Herpes simplex virus and Alzheimer's disease: a Mendelian randomization study
    Kwok, Man Ki
    Schooling, Catherine Mary
    NEUROBIOLOGY OF AGING, 2021, 99 : 101.e11 - 101.e13
  • [29] Childhood obesity and risk of Alzheimer’s disease: a Mendelian randomization study
    Wenxiang Qing
    Yujie Qian
    Archives of Public Health, 82
  • [30] Thyroid Function and the Risk of Alzheimer's Disease: A Mendelian Randomization Study
    Marouli, Eirini
    Yusuf, Lina
    Kjaergaard, Alisa D.
    Omar, Rafat
    Kus, Aleksander
    Babajide, Oladapo
    Sterenborg, Rosalie
    Asvold, Bjorn O.
    Burgess, Stephen
    Ellervik, Christina
    Teumer, Alexander
    Medici, Marco
    Deloukas, Panos
    THYROID, 2021, 31 (12) : 1794 - 1799